Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus METICORTELONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus METICORTELONE.
CORTIFOAM vs METICORTELONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Corticosteroid with glucocorticoid and mineralocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Prednisolone: 5-60 mg orally once daily or divided twice daily; methylprednisolone: 4-48 mg orally once daily or divided twice daily. Dose and duration vary by indication.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life: 3.0-3.5 hours; clinical context: requires multiple daily doses for sustained effect; biological half-life (duration of HPA suppression) longer (~24-36 hours) due to intracellular activity
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Renal: <5% unchanged; hepatic metabolism to inactive metabolites, primarily conjugated and excreted in urine; <2% fecal
Category C
Category C
Corticosteroid
Corticosteroid